Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.4920
0.00 (0.00%)
At close: Jun 5, 2025, 4:00 PM
0.4900
-0.0020 (-0.41%)
After-hours: Jun 5, 2025, 4:40 PM EDT
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Sangamo Therapeutics stock ranges from a low of $2.00 to a high of $10. The average analyst price target of $4.50 forecasts a 814.63% increase in the stock price over the next year.
Price Target: $4.50 (+814.63%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +916.26% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,932.52% | Apr 7, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $2 | Hold | Reiterates | $2 | +306.50% | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,932.52% | Jan 27, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +916.26% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
54.85M
from 57.80M
Decreased by -5.11%
Revenue Next Year
54.34M
from 54.85M
Decreased by -0.93%
EPS This Year
-0.48
from -0.49
EPS Next Year
-0.36
from -0.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 111.7M | 119.7M | 274.7M | ||
| Avg | 54.8M | 54.3M | 105.6M | ||
| Low | 20.4M | 9.7M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.3% | 118.2% | 405.5% | ||
| Avg | -5.1% | -0.9% | 94.3% | ||
| Low | -64.7% | -82.3% | -63.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.41 | -0.22 | 1.08 | ||
| Avg | -0.48 | -0.36 | 0.04 | ||
| Low | -0.54 | -0.49 | -0.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.